JP2022543760A5 - - Google Patents
Info
- Publication number
- JP2022543760A5 JP2022543760A5 JP2022505597A JP2022505597A JP2022543760A5 JP 2022543760 A5 JP2022543760 A5 JP 2022543760A5 JP 2022505597 A JP2022505597 A JP 2022505597A JP 2022505597 A JP2022505597 A JP 2022505597A JP 2022543760 A5 JP2022543760 A5 JP 2022543760A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- disease
- pharmaceutically acceptable
- prodrug
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881225P | 2019-07-31 | 2019-07-31 | |
| US62/881,225 | 2019-07-31 | ||
| US201962926175P | 2019-10-25 | 2019-10-25 | |
| US62/926,175 | 2019-10-25 | ||
| US202063020239P | 2020-05-05 | 2020-05-05 | |
| US63/020,239 | 2020-05-05 | ||
| PCT/US2020/044037 WO2021021909A1 (en) | 2019-07-31 | 2020-07-29 | Dosing regimens for oral complement factor d inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022543760A JP2022543760A (ja) | 2022-10-14 |
| JP2022543760A5 true JP2022543760A5 (https=) | 2023-08-01 |
Family
ID=74230149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505597A Pending JP2022543760A (ja) | 2019-07-31 | 2020-07-29 | 経口補体因子ｄ阻害剤用の投与レジメン |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220257556A1 (https=) |
| EP (1) | EP4003327B1 (https=) |
| JP (1) | JP2022543760A (https=) |
| KR (1) | KR20220041846A (https=) |
| CN (1) | CN114302719A (https=) |
| AU (1) | AU2020323532A1 (https=) |
| BR (1) | BR112022001600A2 (https=) |
| CA (1) | CA3148119A1 (https=) |
| CL (1) | CL2022000257A1 (https=) |
| CO (1) | CO2022001862A2 (https=) |
| CR (1) | CR20220074A (https=) |
| DO (1) | DOP2022000020A (https=) |
| EC (1) | ECSP22014980A (https=) |
| IL (1) | IL289949A (https=) |
| JO (1) | JOP20220011A1 (https=) |
| MX (1) | MX2022001268A (https=) |
| PE (1) | PE20221033A1 (https=) |
| PH (1) | PH12022550149A1 (https=) |
| PY (1) | PY2041390A (https=) |
| TN (1) | TN2022000029A1 (https=) |
| TW (1) | TW202120484A (https=) |
| UY (1) | UY38817A (https=) |
| WO (1) | WO2021021909A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| TWI873092B (zh) | 2018-04-06 | 2025-02-21 | 美商百歐克斯製藥公司 | 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑 |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| WO2020131974A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| BR112021018456A2 (pt) | 2019-03-22 | 2021-11-23 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento |
| AR120173A1 (es) | 2019-10-09 | 2022-02-02 | Biocryst Pharm Inc | Inhibidores del factor d del complemento para administración oral |
| TW202330489A (zh) * | 2021-10-21 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合環類化合物、其製備方法及其在醫藥上的應用 |
| JP2025530036A (ja) * | 2022-09-01 | 2025-09-10 | エフ． ホフマン－ラ ロシュ アーゲー | ビカシナビンの投与レジメン |
| TW202434204A (zh) * | 2023-01-06 | 2024-09-01 | 美商百歐克斯製藥公司 | 用於治療補體介導之疾病之口服劑型及口服給藥方案 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| AU7808198A (en) | 1997-06-03 | 1998-12-21 | Biocryst Pharmaceuticals, Inc. | Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation |
| MX357540B (es) * | 2012-04-06 | 2018-07-13 | Omeros Corp | Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna. |
| MX2014015738A (es) * | 2012-06-28 | 2015-08-06 | Novartis Ag | Derivados de pirrolidina y su uso como moduladores de la senda del complemento. |
| KR20160036568A (ko) | 2013-07-18 | 2016-04-04 | 노파르티스 아게 | 보체 인자 d 억제제로서의 아미노메틸-비아릴 유도체 및 그의 용도 |
| US9732103B2 (en) * | 2014-02-25 | 2017-08-15 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders |
| WO2016088082A1 (en) | 2014-12-05 | 2016-06-09 | Novartis Ag | Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof |
| WO2019057946A1 (en) | 2017-09-25 | 2019-03-28 | F. Hoffmann-La Roche Ag | MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS |
| TWI873092B (zh) * | 2018-04-06 | 2025-02-21 | 美商百歐克斯製藥公司 | 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑 |
| AR120173A1 (es) * | 2019-10-09 | 2022-02-02 | Biocryst Pharm Inc | Inhibidores del factor d del complemento para administración oral |
| PY2062527A (es) * | 2019-10-09 | 2021-09-23 | Biocryst Pharm Inc | Inhibidores del factor d del complemento para administración oral |
-
2020
- 2020-07-29 KR KR1020227003700A patent/KR20220041846A/ko not_active Ceased
- 2020-07-29 US US17/630,692 patent/US20220257556A1/en active Pending
- 2020-07-29 BR BR112022001600A patent/BR112022001600A2/pt unknown
- 2020-07-29 AU AU2020323532A patent/AU2020323532A1/en not_active Abandoned
- 2020-07-29 CA CA3148119A patent/CA3148119A1/en active Pending
- 2020-07-29 JP JP2022505597A patent/JP2022543760A/ja active Pending
- 2020-07-29 TN TNP/2022/000029A patent/TN2022000029A1/en unknown
- 2020-07-29 PE PE2022000169A patent/PE20221033A1/es unknown
- 2020-07-29 CR CR20220074A patent/CR20220074A/es unknown
- 2020-07-29 WO PCT/US2020/044037 patent/WO2021021909A1/en not_active Ceased
- 2020-07-29 JO JOP/2022/0011A patent/JOP20220011A1/ar unknown
- 2020-07-29 EP EP20848440.2A patent/EP4003327B1/en active Active
- 2020-07-29 MX MX2022001268A patent/MX2022001268A/es unknown
- 2020-07-29 CN CN202080055483.9A patent/CN114302719A/zh active Pending
- 2020-07-29 PH PH1/2022/550149A patent/PH12022550149A1/en unknown
- 2020-07-30 TW TW109125794A patent/TW202120484A/zh unknown
- 2020-07-31 UY UY0001038817A patent/UY38817A/es not_active Application Discontinuation
- 2020-07-31 PY PY202002041390A patent/PY2041390A/es unknown
-
2022
- 2022-01-18 IL IL289949A patent/IL289949A/en unknown
- 2022-01-27 DO DO2022000020A patent/DOP2022000020A/es unknown
- 2022-01-31 CL CL2022000257A patent/CL2022000257A1/es unknown
- 2022-02-22 CO CONC2022/0001862A patent/CO2022001862A2/es unknown
- 2022-02-24 EC ECSENADI202214980A patent/ECSP22014980A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022543760A5 (https=) | ||
| Ye et al. | Mild temperature photothermal assisted anti-bacterial and anti-inflammatory nanosystem for synergistic treatment of post-cataract surgery endophthalmitis | |
| AU2016226006B2 (en) | Method of treatment with tradipitant | |
| JP5212849B2 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 | |
| CN103338758B (zh) | 叶酸‑雷米普利组合：具细胞保护性、神经保护性及视网膜保护性的眼科组合物 | |
| JP2012525415A5 (https=) | ||
| RU2018128980A (ru) | Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза | |
| ES2956013T3 (es) | Formulación de equinomicina, método de producción y método de uso de la misma | |
| WO2016029197A1 (en) | Compositions and methods to treat and/or prevent vision disorders of the lens of the eye | |
| Perkovic et al. | Efficacy and safety of iptacopan in patients with IgA nephropathy: Interim results from the Phase 3 APPLAUSE-IgAN study | |
| JP2022533968A5 (https=) | ||
| US20230285373A1 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| AU2025203373A1 (en) | Application Of Fusion Protein In Treating Age-Related Macular Degeneration | |
| JP2015522077A5 (https=) | ||
| EP1299123A2 (en) | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders | |
| JP2003535817A (ja) | αアドレナリン遮断薬の眼への使用 | |
| JP2023548429A5 (https=) | ||
| JP2015523986A (ja) | ラキニモドを使用する眼炎症性疾患の治療 | |
| JP2024516003A5 (https=) | ||
| JP2021138710A5 (https=) | ||
| Garnock-Jones | Ranibizumab: in macular oedema following retinal vein occlusion | |
| JP2025505578A5 (https=) | ||
| US20250381195A1 (en) | Methods of Treating Diabetic Macular Edema | |
| Ewing et al. | Update on avacincaptad pegol for geographic atrophy |